First Results of NURE-Combo: A Phase II Study of Neoadjuvant Nivolumab and Nab-Paclitaxel, Followed by Postsurgical Adjuvant Nivolumab, for Muscle-Invasive Bladder Cancer

医学 无容量 膀胱切除术 紫杉醇 紫杉醇 临床终点 佐剂 膀胱癌 肿瘤科 不利影响 阶段(地层学) 新辅助治疗 泌尿科 癌症 内科学 化疗 外科 临床试验 免疫疗法 乳腺癌 古生物学 生物
作者
Chiara Mercinelli,Marco Moschini,Antonio Cigliola,Benedetta Mattorre,Valentina Tateo,Giuseppe Basile,Laura Lucia Cogrossi,Brigida Anna Maiorano,D. Patanè,Daniele Raggi,Giovanni Luigi Pastorino,Chiara Re,Maurizio Colecchia,Roberta Lucianò,Renzo Colombo,Giorgio Brembilla,Francesco De Cobelli,Alberto Briganti,Dean C. Pavlick,Jeffrey S. Ross
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (35): 4196-4205 被引量:5
标识
DOI:10.1200/jco.24.00576
摘要

PURPOSE To evaluate the activity and safety of nivolumab with nab-paclitaxel as neoadjuvant therapy, followed by radical cystectomy (RC) and postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer (MIBC). PATIENTS AND METHODS Eligible patients had an Eastern Cooperative Oncology Group performance status of ≤1 and a T2-4aN0-1M0 stage with >50% urothelial carcinoma histology and were ineligible for or refused cisplatin-based chemotherapy. Patients received four cycles of nivolumab 360 mg once every 3 weeks + nab-paclitaxel 125 mg/m 2 once on days 1 and 8, every 3 weeks, followed by RC, and then adjuvant nivolumab 360 mg once every 3 weeks × 13 cycles. The primary end point was the pathologic complete response (CR) rate (ypT0N0). Secondary end points were major pathologic response (ypT≤1N0), safety, event-free survival (EFS), and overall survival. RESULTS Thirty-one patients were enrolled from December 2021 to June 2023; 19 (61.3%) had a cT2 stage, two (6.5%) had N1 stage, and 16 (51.6%) had a variant histology. Five patients (16.1%) received less than four full courses of neoadjuvant treatment because of treatment-related adverse events (TRAEs). Grade 3/4 TRAEs occurred in eight patients (25.8%). Twenty-eight patients underwent RC, and three refused RC after evidence of clinical CR and received a redo transurethral resection of the bladder tumor (reTURBT). The trial met its primary end point: 10 patients (32.3%; 95% CI, 16.7 to 51.4) achieved an ypT0N0 response. By including those who underwent reTURBT, 22 (70.9%; 95% CI, 55 to 87) achieved an ypT≤1N0-x response. After a median follow-up of 12 months (range, 5-22), two patients had a disease relapse after surgery. The 12-month EFS was 89.8% (95% CI, 79.5 to 100). CONCLUSION To our knowledge, the first results from NURE-Combo trial suggest that this combination could expand the therapeutic opportunities of immune-chemotherapy in patients with MIBC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
杰尼龟的鱼完成签到 ,获得积分10
刚刚
安然完成签到 ,获得积分10
1秒前
张希伦完成签到 ,获得积分10
1秒前
任性翠安完成签到 ,获得积分10
5秒前
dong完成签到 ,获得积分10
7秒前
神说完成签到,获得积分0
9秒前
量子星尘发布了新的文献求助10
15秒前
Aimee完成签到 ,获得积分10
15秒前
徐彬荣完成签到,获得积分10
16秒前
研友_8yN60L完成签到,获得积分10
17秒前
搜集达人应助科研通管家采纳,获得10
17秒前
光亮的自行车完成签到 ,获得积分10
17秒前
李东东完成签到 ,获得积分10
32秒前
王多肉完成签到,获得积分10
36秒前
Iiiilr完成签到 ,获得积分10
37秒前
杨幂完成签到,获得积分10
38秒前
45秒前
hellokitty完成签到,获得积分10
48秒前
48秒前
小四发布了新的文献求助10
49秒前
55秒前
西瓜完成签到 ,获得积分10
55秒前
包容的忆灵完成签到 ,获得积分10
58秒前
高兴尔冬发布了新的文献求助10
1分钟前
xiang完成签到 ,获得积分0
1分钟前
小四完成签到,获得积分10
1分钟前
FashionBoy应助slayers采纳,获得30
1分钟前
量子星尘发布了新的文献求助10
1分钟前
黑眼圈完成签到 ,获得积分10
1分钟前
jia完成签到 ,获得积分10
1分钟前
如履平川完成签到 ,获得积分10
1分钟前
科目三应助忧伤的步美采纳,获得10
1分钟前
大椒完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
wisdom完成签到,获得积分10
1分钟前
slayers发布了新的文献求助30
1分钟前
1分钟前
e746700020完成签到,获得积分10
1分钟前
高兴尔冬完成签到,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022